Critical reappraisal of remdesivir investigational trials in COVID-19

Brouqui, P.
Giraud-Gatineau, A.
Raoult, D.

Open link

Publication date

January 2020

DOI

10.1016/j.nmni.2020.100745

Publisher

Elsevier BV

Abstract

International audienceDuring disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention during the COVID-19 pandemic. (C) 2020 The Author(s). Published by Elsevier Ltd

Extracted data

We use cookies to provide a better user experience.

Data Protection

Critical reappraisal of remdesivir investigational trials in COVID-19

Abstract

Extracted data

Critical reappraisal of remdesivir investigational trials in COVID-19

Abstract

Extracted data

Related items

Related items